Clinical Trial Update: Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for afatinib plus paclitaxel as second-line therapy in advanced gastric and gastroesophageal junction cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Afatinib (afatinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Yonsei University | Conditions: Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 | Status: COMPLETED